These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 36293518)

  • 21. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression.
    Mungamuri SK; Vijayasarathy K
    Crit Rev Oncog; 2020; 25(1):57-70. PubMed ID: 32865911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome.
    Kobayashi T; Iwaki M; Nakajima A; Nogami A; Yoneda M
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
    Douhara A; Moriya K; Yoshiji H; Noguchi R; Namisaki T; Kitade M; Kaji K; Aihara Y; Nishimura N; Takeda K; Okura Y; Kawaratani H; Fukui H
    Mol Med Rep; 2015 Mar; 11(3):1693-700. PubMed ID: 25421042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dysbiosis and liver diseases (Review).
    Nishikawa H; Fukunishi S; Asai A; Yokohama K; Ohama H; Nishiguchi S; Higuchi K
    Int J Mol Med; 2021 Sep; 48(3):. PubMed ID: 34328191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).
    Duarte SMB; Stefano JT; Oliveira CP
    Ann Hepatol; 2019; 18(3):416-421. PubMed ID: 31036494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.
    Carpi RZ; Barbalho SM; Sloan KP; Laurindo LF; Gonzaga HF; Grippa PC; Zutin TLM; Girio RJS; Repetti CSF; Detregiachi CRP; Bueno PCS; Mazuqueli Pereira ESB; Goulart RA; Haber JFDS
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbiota, Liver Diseases, and Alcohol.
    Cassard AM; Gérard P; Perlemuter G
    Microbiol Spectr; 2017 Aug; 5(4):. PubMed ID: 28840806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression.
    Chen D; Le TH; Shahidipour H; Read SA; Ahlenstiel G
    Cells; 2019 Oct; 8(11):. PubMed ID: 31717860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.
    Borrelli A; Bonelli P; Tuccillo FM; Goldfine ID; Evans JL; Buonaguro FM; Mancini A
    Redox Biol; 2018 May; 15():467-479. PubMed ID: 29413959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut dysbacteriosis and intestinal disease: mechanism and treatment.
    Meng X; Zhang G; Cao H; Yu D; Fang X; de Vos WM; Wu H
    J Appl Microbiol; 2020 Oct; 129(4):787-805. PubMed ID: 32277534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The gut-liver axis: how the gut promotes liver disease].
    Demir M; Tacke F
    Inn Med (Heidelb); 2022 Oct; 63(10):1028-1035. PubMed ID: 36053302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
    Chu H; Duan Y; Yang L; Schnabl B
    Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
    Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
    Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.